the endothelial-haemostatic factors was, however, related to homocyst(e)ine levels. Mid-term fola... more the endothelial-haemostatic factors was, however, related to homocyst(e)ine levels. Mid-term folate Background. Haemodialysis patients exhibit an excessive burden of atherothrombotic disease, which is not supplementation decreased plasma homocyst(e)ine levels significantly without achieving normal values. explained adequately by traditional risk factors. Hyperhomocyst(e)inaemia, a consistent finding in No significant change of endothelial-haemostatic markers was observed, however, despite the drop in uraemic patients, is now widely recognized as an independent risk factor for vascular disease. The aim plasma homocyst(e)ine. Conclusions. Hyperhomocyst(e)inaemia is associated of this study was to examine the hypothesis that hyperhomocyst(e)inaemia is associated with cardiovas-with increased cardiovascular risk in haemodialysis patients. Folate supplementation was partially effective cular complications in dialysed patients. Methods. In a cohort of 63 stable chronic haemodia-in lowering hyperhomocyst(e)inaemia, but its usefulness in terms of reduction in cardiovascular morbid-lysis patients, we examined the causal relationship between hyperhomocyst(e)inaemia and vascular endo-ity and mortality remains to be determined in prospective trials. thelial and haemostatic function. All their markers were determined before and after an 8-week course of Key words: homocyst(e)ine; haemostatic factors; endoa 10 mg per day oral folate supplementation, a manthelium; haemodialysis; chronic renal failure oeuvre known to decrease hyperhomocyst(e)inaemia in uraemic patients. Results. History of at least one cardiovascular
the endothelial-haemostatic factors was, however, related to homocyst(e)ine levels. Mid-term fola... more the endothelial-haemostatic factors was, however, related to homocyst(e)ine levels. Mid-term folate Background. Haemodialysis patients exhibit an excessive burden of atherothrombotic disease, which is not supplementation decreased plasma homocyst(e)ine levels significantly without achieving normal values. explained adequately by traditional risk factors. Hyperhomocyst(e)inaemia, a consistent finding in No significant change of endothelial-haemostatic markers was observed, however, despite the drop in uraemic patients, is now widely recognized as an independent risk factor for vascular disease. The aim plasma homocyst(e)ine. Conclusions. Hyperhomocyst(e)inaemia is associated of this study was to examine the hypothesis that hyperhomocyst(e)inaemia is associated with cardiovas-with increased cardiovascular risk in haemodialysis patients. Folate supplementation was partially effective cular complications in dialysed patients. Methods. In a cohort of 63 stable chronic haemodia-in lowering hyperhomocyst(e)inaemia, but its usefulness in terms of reduction in cardiovascular morbid-lysis patients, we examined the causal relationship between hyperhomocyst(e)inaemia and vascular endo-ity and mortality remains to be determined in prospective trials. thelial and haemostatic function. All their markers were determined before and after an 8-week course of Key words: homocyst(e)ine; haemostatic factors; endoa 10 mg per day oral folate supplementation, a manthelium; haemodialysis; chronic renal failure oeuvre known to decrease hyperhomocyst(e)inaemia in uraemic patients. Results. History of at least one cardiovascular
Uploads
Papers by m lisri